

ASCO 2014

Highlights


Dr. Diane Cleverley

Personal Healthcare Information



ALTT0: High survival rates for all early breast cancer treatment groups

- One of the largest breast cancer trials ever, 6,281 patients, worldwide
- All arms had impressive disease-free 4 year survival of 95% (Lap + Tras), 95% (Tras, then Lap) and 94% Drug alone)
- Some “disappointment” that a difference could not be detected
- Slightly higher signal seen with HR- for Tras then Lap treatment, but it was not significant



WATSON-like computer gives treatment advice to oncologists

- An MD Anderson study showed that Oncology Expert Advisor, a Watson-like computer, was able to generate patient case summaries and accurately recommended standard of care treatments more than 80% of the time
- Questions remain regarding:
 - How the system incorporates patient preference
 - How “correctness” is actually defined
 - How to measure improvement to current human decision making
 - How to decide if there is a value added to the patient

The IOM reports that the gaps in cancer care are expanding


Demands include:

- Increasing number of cancer cases
- the expanding number of long-term survivors
- a shortage of cancer care health professionals
- more adjuvant and multimodal therapies

Healthcare professionals should communicate with patients including:


- Treatment goals
- How long they are likely to live
- Cure or increase survival?
- Will chemo make them feel better or worse?
- When to consider palliative care and hospice

Out-of-pocket costs, termed financial toxicity, are a side effect of this disease.



Obese premenopausal women with ER+ breast cancer may be at greater risk; but weight loss may reduce inflammation biomarkers

- Obese premenopausal women with estrogen receptor positive disease (ER+) experienced a much higher breast cancer mortality rate (21.5%) after 10 years than their normal weight counterparts (16.6%)
- The difference was significant ($p < .00001$)
- Another study, SHAPE-2 study showed reductions in inflammation biomarkers in postmenopausal ER+ women whose breast cancer was in remission when they participated in a program that resulted in a $\geq 5\%$ weight loss






Personal Healthcare Information, LLC
<http://personalhealthinfo.weebly.com/>



Chemotherapy +Hormone deprivation increases survival in metastatic prostate cancer

- Dr. Christopher Sweeney, Dana Farber Institute, announced results of the E3805 trial comparing “upfront” chemotherapy plus androgen deprivation therapy (ADT) with treatment with ADT alone in men with metastatic prostate cancer
- In 790 men, median overall survival was 57.6 months in the ADT plus chemotherapy arm and 44.0 months in the ADT arm
- The difference was significant ($p = 0.0003$)

Primary Endpoint: Overall Survival




SELECT: Lenvatinib (a multityrosine kinase inhibitor) Improves PFS in Thyroid Cancer

392 patients over 2 years

- “What blew me away—and what should blow you away—are these response rates,” A. Dimitrios Colevas, MD, of Stanford Cancer Institute said about the trial results. “This is a truly amazing disease-free survival
- 20 patients died on lenvatinib compared with six who received placebo, and investigators thought six fatalities (2%) were directly due to the use of lenvatinib

Primary Endpoint: Kaplan-Meier Estimate of PFS



Abbreviations: CI, confidence interval; HR, hazard ratio; NR, not reached; PFS, progression-free survival.

<http://am.asco.org/select-lenvatinib-improves-pfs-thyroid-cancer>

